Pralatrexate - From bench to bedside

Drugs of Today

Volumn 46, Issue 2, 2010, Pages 91-99

  Zain, Jasmine M ^a   Marchi, E ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYANOCOBALAMIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EDATREXATE; FOLIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; PACLITAXEL; PEMETREXED; PRALATREXATE; PROBENECID; REDUCED FOLATE CARRIER;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLOOD TOXICITY; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; EXFOLIATIVE DERMATITIS; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; T CELL LYMPHOMA; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

AMINOPTERIN; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FOLIC ACID ANTAGONISTS; HUMANS; NEOPLASMS;

EID: 77953585585     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.2.1439260     Document Type: Review

References (28)

1. Matherly, L., Hou, Z., Deng, Y. Human reduced folate carrier: Translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007, 26(1): 111-28. (Pubitemid 46452186)
2. Whetstine, J.R., Flatley, R.M., Matherly, L.H. The human reduced folate carrier gene is ubiquitously expressed in normal human tissues: Identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002, 367 (Pt. 3): 629-40.
3. Moscow, J.A. Gong, M., He, R. et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate resistant breast cancer cell. Cancer Res 1995, 55(17): 3790-4.
4. Farber, S., Diamond, L.K., Wolff, J. Temporary remission in acute leukemia in children produced by folic acid antagonist 4-amethopteroyl glutamic acid. N Engl J Med 1948, 238(23): 787-93.
5. Bertino, J. The mechanism of action of the folate antagonists in man. Cancer Res 1963, 23: 1286-306.
6. Sirotnak, F.M., Tolner, B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999, 19: 91-122. (Pubitemid 29380598)
7. Sirotnak, F.M., DeGraw, J.I., Moccio, D.M., Samuel, L.L., Goutas, L.J.. New folate analogs of the 10-deazaaminopterin series: Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 1984, 12(1): 18-25.
8. DeGraw, J.I., Colwell, W., Piper, J.R., Sirotnak, F.M. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J. Med Chem 1993, 36(15): 2228-31.
9. Wang, E.S., O'Connor, O., She, Y., Zeletnek, A.D., Sirotnak, F.M., Moore, M.A. Activity of a novel anti-folate (pralatrexate, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44(6): 1027-35. (Pubitemid 36417003)
10. Izbicka, E., Diaz, A., Streeper, R., Wick, M., Campos, D., Steffen, R., Saunders, M. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009, 64(5): 993-9.
11. Schmid, F.A., Sirotnak, F.M., Otter, G.M., DeGraw, J.I. New folate analogs of the 10-deaza-aminopterin series: Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985, 69(5): 551-3.
12. Sirotnak, F.M., DeGraw, J.I., Colwell, W.T., Piper, J.R. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998, 42(4): 313-8.
13. Hoovis, M., Chu, M. Enhancement of the antiproliferative action of 1-D-arabinofuranosylcytosine by methotrexate in murine leukemia cells. Cancer Res 1973, 33(3): 521-5.
14. Khouri, I.F., Romaguera, J., Kantarjian, H.et al. Hyper-CVAD and high dose methotrexate followed by stem cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16(12): 3803-9.
15. Toner, L.E., Vrhovac, R., Smith, E.A. et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12(3 pt 1): 924-32.
16. Marchi, E., Paoluzzi, L., Venkatraman, S.E., O'Connor, O. Pralatrexate (PDX) compliments the activity of the proteasome inhibitor bortezomib (B) in in vitro models of lymphoid 7-cell malignancies. 50th Ann Meet Am Soc Hematol (December 6-9, San Francisco) 2008, Abst 3619.
17. Krug, L.M., Ng, K.K., Kris, M.G. et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 2000, 6(9): 3493-8.
18. Krug, L.M., Azzoli, C.G., Kris, M.G. et al. 10-propargyl-10- deazaaminopterin: An antifolate with activity in patients with previously treated non-small-cell lung cancer. Clin Cancer Res 2003, 9(6): 2072-8.
19. Azzoli C.G., Krug, L., Miller, V. et al. Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid supplementation in patients (pts) with advanced non-small-cell lung cancer. 43rd Annu Meet Am Soc Clin Oncol (June 1-5, Chicago) 2007, Abst 13006.
20. Fury, M.G., Krug, L.M., Azzoli, C.G. et al. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol 2005, 57(5): 1-7.
21. Azzoli, C.G., Krug, L.M., Gomez, J. et al. A phase I study of pralatrexate in combination with paclitaxel or decetaxel in patients with advanced solid tumors. Clin Cancer Res 2007, 13(9): 2692-8.
22. Krug, L.M., Heelan, R.T., Kris, M.G., Venkatraman, E., Sirotnak, F.M. Phase II study of pralatrexate in patients with unresectable malignant pleural mesothelioma. J Thoracic Oncol 2007, 2(4): 317-20.
23. O'Connor, O., Horwitz, S., Hamlin, P. et al. Phase II-I-II study of two different doses and schedules of pralatexate, a high affinity substrate for the reduced folate carrier in patients with relapsed or refractory lymphoma reveals marked activity in T cell malignancies. J Clin Oncol 2009, 27(26): 4357-64.
24. Mould, D.R., Sweeney, K., Duffull, S.B., Neylon, E. et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2009, 86(2): 190-6.
25. O'Connor, O., Pro, B., Pinter-Brown, L. et al. Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 45th Annu Meet Am Soc Clin Oncol (May 29-June 2, Orlando) 2009, Abst 8561.
26. Cheson, B.D., Pfistner, B., Juweid, M.E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5): 579-86.
27. Horwitz, S., Zain, J., Connor, O. Pralatrexate (pralatrexate) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose-finding trial. 50th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2008, Abst 1569.
28. Horwitz, S., Vose, J., O'Connor, O. A phase 1/2A open label study of pralatrexate and gemcitiabine in patients with relapsed or refractory lymphoproliferative malignancies. 51st Annu Meet Am Soc Hematol (December 5-8, New Orleans) 2009, Abst 1570.